Published in Antimicrob Agents Chemother on March 01, 2004
Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev (2008) 17.77
Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2007) 7.84
Polymyxins revisited. Clin Microbiol Rev (2008) 3.16
Identification of a new allelic variant of the Acinetobacter baumannii cephalosporinase, ADC-7 beta-lactamase: defining a unique family of class C enzymes. Antimicrob Agents Chemother (2005) 1.88
Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. J Clin Microbiol (2008) 1.46
Mutations of the ompK36 porin gene and promoter impact responses of sequence type 258, KPC-2-producing Klebsiella pneumoniae strains to doripenem and doripenem-colistin. Antimicrob Agents Chemother (2013) 1.44
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother (2010) 1.40
Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS One (2012) 1.40
In vitro evaluation of antibiotic synergy for polymyxin B-resistant carbapenemase-producing Klebsiella pneumoniae. J Clin Microbiol (2010) 1.35
Successful treatment of septic shock due to pan-resistant Acinetobacter baumannii using combined antimicrobial therapy including tigecycline. Eur J Clin Microbiol Infect Dis (2006) 1.29
Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother (2013) 1.27
In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases. Ann Clin Microbiol Antimicrob (2006) 1.19
In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. PLoS One (2011) 1.14
In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother (2008) 1.14
A focus on intra-abdominal infections. World J Emerg Surg (2010) 1.10
Characterization of porin expression in Klebsiella pneumoniae Carbapenemase (KPC)-producing K. pneumoniae identifies isolates most susceptible to the combination of colistin and carbapenems. Antimicrob Agents Chemother (2013) 1.10
Activity of cecropin A-melittin hybrid peptides against colistin-resistant clinical strains of Acinetobacter baumannii: molecular basis for the differential mechanisms of action. Antimicrob Agents Chemother (2006) 1.07
Combination antibiotic treatment versus monotherapy for multidrug-resistant, extensively drug-resistant, and pandrug-resistant Acinetobacter infections: a systematic review. Eur J Clin Microbiol Infect Dis (2014) 1.00
The role of carbapenems in initial therapy for serious Gram-negative infections. Crit Care (2008) 1.00
In vitro activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother (2006) 0.95
A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother (2013) 0.94
Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother (2015) 0.91
Synergistic effects and antibiofilm properties of chimeric peptides against multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother (2013) 0.90
Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases. Case Rep Med (2011) 0.88
The use of intravenous colistin among children in the United States: results from a multicenter, case series. Pediatr Infect Dis J (2013) 0.86
In vitro evaluation of ciclopirox as an adjuvant for polymyxin B against gram-negative bacteria. J Antibiot (Tokyo) (2015) 0.83
Combinations of β-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant Staphylococcus aureus. PLoS One (2015) 0.83
A 4-year surveillance of antimicrobial resistance patterns of Acinetobacter baumanni in a university-affiliated hospital in China. J Thorac Dis (2013) 0.82
Extensively drug-resistant Acinetobacter baumannii in a Thai hospital: a molecular epidemiologic analysis and identification of bactericidal Polymyxin B-based combinations. Antimicrob Resist Infect Control (2015) 0.81
Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. Eur J Clin Microbiol Infect Dis (2005) 0.80
Activity of the colistin-rifampicin combination against colistin-resistant, carbapenemase-producing Gram-negative bacteria. J Chemother (2013) 0.79
Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii. Int J Nanomedicine (2016) 0.77
Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital. BMC Infect Dis (2017) 0.75
Successful management of an outbreak due to carbapenem-resistant Acinetobacter baumannii in a neonatal intensive care unit. Eur J Pediatr (2014) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev (1996) 13.25
A method for testing for synergy with any number of agents. J Infect Dis (1978) 9.52
Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis (1999) 5.90
Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet (1994) 5.73
Evaluation of a new Etest for detecting metallo-beta-lactamases in routine clinical testing. J Clin Microbiol (2002) 3.38
Worldwide emergence of carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother (1998) 2.94
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother (2003) 2.68
Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents (1999) 2.64
Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, interinstitutional spread, and relation to antibiotic usage. Clin Infect Dis (2000) 2.50
Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother (2003) 2.19
Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect (2002) 1.95
Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis (2003) 1.91
In vitro activities of nontraditional antimicrobials against multiresistant Acinetobacter baumannii strains isolated in an intensive care unit outbreak. Antimicrob Agents Chemother (2000) 1.43
Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis (2001) 1.42
Successful treatment of ventriculitis due to carbapenem-resistant Acinetobacter baumannii with intraventricular colistin sulfomethate sodium. Clin Infect Dis (1999) 1.36
Polymyxin B and rifampin: new regimen for multiresistant Serratia marcescens infections. Antimicrob Agents Chemother (1977) 1.30
Combination therapy as a tool to prevent emergence of bacterial resistance. Infection (1999) 1.17
Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia. J Infect Dis (1980) 1.14
In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model. Antimicrob Agents Chemother (1999) 1.12
Sulfamethoxazole-trimethoprim-polymyxin therapy of serious multiply drug-resistant Serratia infections. Antimicrob Agents Chemother (1976) 1.11
Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI and Cecropin P1. Antimicrob Agents Chemother (2001) 1.10
Infections caused by imipenem-resistant Acinetobacter calcoaceticus biotype anitratus. J Infect Dis (1993) 1.03
Comparative activities of polycationic peptides and clinically used antimicrobial agents against multidrug-resistant nosocomial isolates of Acinetobacter baumannii. J Antimicrob Chemother (2000) 1.02
Pseudomonas cepacia tricuspid endocarditis: treatment with trimethoprim, sulfonamide, and polymyxin B. J Infect Dis (1973) 0.89
Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis (2004) 9.21
Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli. J Infect Dis (2013) 3.56
Molecular epidemiological analysis of Escherichia coli sequence type ST131 (O25:H4) and blaCTX-M-15 among extended-spectrum-β-lactamase-producing E. coli from the United States, 2000 to 2009. Antimicrob Agents Chemother (2012) 2.17
Comparison of Escherichia coli ST131 pulsotypes, by epidemiologic traits, 1967-2009. Emerg Infect Dis (2012) 2.05
Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis (2008) 1.97
Considerations in control and treatment of nosocomial infections due to multidrug-resistant Acinetobacter baumannii. Clin Infect Dis (2003) 1.91
Efficacy of interferon alpha-2b and ribavirin against West Nile virus in vitro. Emerg Infect Dis (2002) 1.75
In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Agents Chemother (2010) 1.40
Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis (2010) 1.35
Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology. Clin Infect Dis (2004) 1.30
Identification of carbapenem-resistant klebsiella pneumoniae harboring KPC enzymes in New Jersey. Microb Drug Resist (2007) 1.27
Quinolone-resistant Haemophilus influenzae in a long-term-care facility: nucleotide sequence characterization of alterations in the genes encoding DNA gyrase and DNA topoisomerase IV. Antimicrob Agents Chemother (2004) 1.20
Fluoroquinolone-resistant Streptococcus agalactiae: epidemiology and mechanism of resistance. Antimicrob Agents Chemother (2005) 1.09
Susceptibility profiles, molecular epidemiology, and detection of KPC-producing Escherichia coli isolates from the New York City vicinity. J Clin Microbiol (2010) 1.09
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin. Antimicrob Agents Chemother (2004) 1.04
Identification of CTX-M β-lactamases among Escherichia coli from the community in New York City. Diagn Microbiol Infect Dis (2012) 1.01
Nosocomial antibiotic resistance in multiple gram-negative species: experience at one hospital with squeezing the resistance balloon at multiple sites. Clin Infect Dis (2002) 0.99
Subacute endocarditis caused by Gemella haemolysans and a review of the literature. Scand J Infect Dis (2004) 0.98
Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI Summit. Clin Infect Dis (2008) 0.97
Corynebacterium bovis line related septicemia: a case report and review of the literature. Scand J Infect Dis (2008) 0.95
Polymyxin-resistant clinical isolates of Escherichia coli. Antimicrob Agents Chemother (2010) 0.94
Klebsiella pneumoniae carbapenemases in Enterobacteriaceae: history, evolution, and microbiology concerns. Pharmacotherapy (2012) 0.90
Increased mortality associated with a clonal outbreak of ceftazidime-resistant Klebsiella pneumoniae: a case-control study. Infect Control Hosp Epidemiol (2005) 0.90
Endocarditis due to Corynebacterium amycolatum. J Med Microbiol (2008) 0.90
Polymyxin Combination Therapy and the Use of Serum Bactericidal Titers in the Management of KPC-Producing Klebsiella pneumoniae Infections: A Report of 3 Cases. Case Rep Med (2011) 0.88
Tricuspid valve endocarditis caused by Haemophilus parainfluenzae: a case report and review of the literature. Diagn Microbiol Infect Dis (2009) 0.86
Community-associated Escherichia coli harboring CTX-M β-lactamases from urine cultures from pediatric patients. Antimicrob Agents Chemother (2012) 0.86
Impact of contact and droplet precautions on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus infection. Infect Control Hosp Epidemiol (2007) 0.85
Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs. J Antimicrob Chemother (2013) 0.83
An outbreak of domestically acquired typhoid fever in Queens, NY. Arch Intern Med (2004) 0.81
Unrelated strain methicillin-resistant Staphylococcus aureus colonization of health care workers in a neonatal intensive care unit: findings of an outbreak investigation. Am J Infect Control (2013) 0.81
Mycobacterial infection as a precursor to sarcoid-like, corticosteroid-responsive, diffuse granulomatous disease. Int J Infect Dis (2006) 0.79
Comparison of a hospital-wide antibiogram with that of an associated long-term care facility. J Am Geriatr Soc (2012) 0.79
Identification of extended-spectrum-β-lactamase-positive Klebsiella pneumoniae urinary tract isolates harboring KPC and CTX-M β-lactamases in nonhospitalized patients. Antimicrob Agents Chemother (2013) 0.77
Phenotypic and genotypic screening and clonal analysis of carbapenem-resistant Klebsiella pneumoniae at a single hospital. Microb Drug Resist (2011) 0.77
Thyrotoxic hypokalemic periodic paralysis in a Hispanic male. J Natl Med Assoc (2002) 0.77
Levofloxacin-resistant-Streptococcus mitis endophthalmitis: a unique presentation of bacterial endocarditis. J Med Microbiol (2009) 0.75
Use of daptomycin for the treatment of methicillin-resistant coagulase-negative staphylococcal ventriculitis. Case Rep Med (2012) 0.75
In memoriam: James J. Rahal Jr, MD. Clin Infect Dis (2011) 0.75